He was also counseled on what to expect with the new medication, including the possibility of experiencing gastrointestinal side effects with GLP-1 RA therapy and how to minimize them
Clinical trials show average losses of around 15% of body weight for semaglutide and 2022% for tirzepatide, but those are averages over 68+ weeks, not a 30-day result
Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
Some patients benefit from temporary use of over-the-counter remedies like bismuth subsalicylate or loperamide, though these should be discussed with your healthcare provider first